<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OALibJ</journal-id><journal-title-group><journal-title>Open Access Library Journal</journal-title></journal-title-group><issn pub-type="epub">2333-9705</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/oalib.1111004</article-id><article-id pub-id-type="publisher-id">OALibJ-130196</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject><subject> Business&amp;Economics</subject><subject> Chemistry&amp;Materials Science</subject><subject> Computer Science&amp;Communications</subject><subject> Earth&amp;Environmental Sciences</subject><subject> Engineering</subject><subject> Medicine&amp;Healthcare</subject><subject> Physics&amp;Mathematics</subject><subject> Social Sciences&amp;Humanities</subject></subj-group></article-categories><title-group><article-title>
 
 
  Cross-Sectional Perspective Study of Post-COVID Syndrome Characteristics in Benghazi, Libya
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Asma</surname><given-names>M. Buzgeia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nuri</surname><given-names>H. Salem Badi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fatma</surname><given-names>Mohamed Bushaala Ali</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nazik</surname><given-names>M. Ali Hamad</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Statistics, Faculty of Science, University of Benghazi, Benghazi, Libya</addr-line></aff><aff id="aff1"><addr-line>Department of Pharmaceutics, Faculty of Pharmacy, University of Benghazi, Benghazi, Libya</addr-line></aff><aff id="aff3"><addr-line>Department of Microbiology, Libyan Academy of Postgraduates, Benghazi, Libya</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>12</month><year>2023</year></pub-date><volume>10</volume><issue>12</issue><fpage>1</fpage><lpage>14</lpage><history><date date-type="received"><day>18,</day>	<month>November</month>	<year>2023</year></date><date date-type="rev-recd"><day>25,</day>	<month>December</month>	<year>2023</year>	</date><date date-type="accepted"><day>28,</day>	<month>December</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Post-COVID syndrome (PCS) is associated with symptoms that persist after curing from SARS-CoV-2 infection. According to WHO, it is a disorder that typically requires at least 2 months to manifest before being diagnosed, and occurs 3 months after the initiation of COVID-19. Fatigue, dyspnea, headaches, joints, chest pains, abnormalities of taste and smell, coughing, hair loss, sleeplessness cardiac and gastrointestinal problems are examples of persistent symptoms. A cross-sectional study is with 325 participants from Benghazi. Prior to taking part in the trial, the individuals in this study had been infected with the coronavirus for at least two months. The majority of participants’ age was between 40 and 69 years, regarding the symptoms that were reported after infection. Fatigue was the most common response. Also, 71.4% of the participants had a mild infection The majority of patients received vitamins, analgesics, and minerals treatment (37.9%). The results were divided into a strong relationship with a significant p-value of less than (0.05) and a weak or insignificant (p-value &gt; 0.05). In conclusion, fatigue, new loss of sense of taste, and smell and cough were the most common persistent symptoms in patients for a period of more than two months. Age and gender were a predictor for PCS while treatment protocol and symptoms such as cough, diarrhea, and headache were not a sign for PCS.
 
</p></abstract><kwd-group><kwd>Comorbidity</kwd><kwd> Infection</kwd><kwd> Persist</kwd><kwd> Symptoms and Treatment Protocol</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Benghazi experienced a Coronaviruses pandemic like every other big city in the world. In fact, according to Benghazi’s medical anti-coronaviruses committee, on the seventh of April 2020, documented it was the first case of COVID-19, who was a male aged 55 years old, had lung issues, and arrived in Benghazi from T&#252;rkiye via Tunisia.</p><p>The severe acute respiratory syndrome coronavirus (SARS-CoV-2), which was originally identified in November 2002, and the Middle East respiratory syndrome coronavirus (MERS-CoV), which was first revealed in September 2012, were both caused by Coronaviruses [<xref ref-type="bibr" rid="scirp.130196-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.130196-ref2">2</xref>] .</p><p>Infection occurs by tremendous droplets produced by symptomatic patients coughing and sneezing, but it can also come from asymptomatic individuals and begin before the onset of symptoms [<xref ref-type="bibr" rid="scirp.130196-ref3">3</xref>] . Such diseased droplets can deposit on surfaces and propagate 1 - 2 meters. The virus can survive on surfaces for days, but simple disinfectants like hydrogen peroxide and sodium hypochlorite kill them in just a minute [<xref ref-type="bibr" rid="scirp.130196-ref4">4</xref>] . Therefore, respiratory droplet and contact transmission are the main ways that SARS-CoV-2 spreads from person to person. The virus can be spread by infected people both throughout the incubation period and the recovery period [<xref ref-type="bibr" rid="scirp.130196-ref5">5</xref>] .</p><p>The majority of SARS-CoV-2 infected recipients are still asymptomatic. However, in symptomatic patients, the disease’s clinical manifestations typically take from two to five days or so to manifest themselves. With a median of 14 days, the time from the onset of COVID-19 symptoms to mortality ranged from 6 to 41 days [<xref ref-type="bibr" rid="scirp.130196-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.130196-ref7">7</xref>] . Fever, cough, and exhaustion are just a few of the many symptoms of COVID-19 that can differ from person to person [<xref ref-type="bibr" rid="scirp.130196-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.130196-ref8">8</xref>] . Other symptoms include sputum production, tachycardia, headache, hemoptysis, diarrhea, dyspnea, lymphopenia, and depression.</p><p>The progression of COVID-19 into a severe and critical stage has been linked to elderly subjects, males, underlying comorbidities like hypertension, diabetes, obesity, chronic lung diseases, heart diseases, liver diseases, kidney diseases, tumors, clinically apparent immunodeficiency, and pregnancy [<xref ref-type="bibr" rid="scirp.130196-ref9">9</xref>] .</p><p>Several studies have shown a wide range of symptoms associated with post-acute COVID-19 syndrome, according to WHO, it is a disorder that typically requires at least 2 months to manifest before being diagnosed, occurs 3 months after the initiation of COVID-19, and cannot be explained by another illness. The underlying disease’s symptoms may return or they may differ from those felt during an acute COVID-19 episode. Over time, symptoms may also shift or come back. Patients who initially only experienced mild to moderate acute symptoms and did not require hospitalization still experience long-term problems. Fatigue and dyspnea are two of these symptoms. Other less common symptoms include mental and cognitive impairments, headaches, myalgia, joint and chest pains, abnormalities of taste and smell, coughing, hair loss, sleeplessness, wheezing, rhinorrhea, sputum, cardiac and gastrointestinal problems. After being released from the hospital or when the symptoms first appear, they may last up to six months. Long COVID has also been linked to less common symptoms including cold, flushing, earache, and visual impairments. These symptoms are comparable to those of people with prior viral illness epidemics (SARS and MERS) [<xref ref-type="bibr" rid="scirp.130196-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.130196-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.130196-ref12">12</xref>] .</p><p>The purpose of this research was to investigate and get an understanding of the post-coronavirus syndrome (COVID-19) symptoms among Benghazi’s city survivors. Factors that aggravate or tag signs and symptoms of post-COVID syndrome (PCS) also evaluate the effective treatment between those patients.</p></sec><sec id="s2"><title>2. Methodology</title><p>In across-sectional epidemiological study of 325 Benghazi’s residents, Regardless of their gender or age, these patients had been diagnosed with Coronavirus at least two months, prior were asked to complete a specially created questionnaire regarding their current health status and any lingering symptoms, they had after acquiring the virus. More than 200 others also took part in the study by using a special web link and responding to the same survey. Those individuals who completed the survey were asked to indicate their acceptance to participate in the study at the outset of the questionnaire. 24 subjects out of a total of 325 were excluded due to their responses were insufficient. This research was conducted during the period of 10 months from December 2021 to September 2022.</p><p>Analogous to the questionnaire, it has eight components, as shown in <xref ref-type="table" rid="table1">Table 1</xref>.</p></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Baseline Characteristics of Study Participants</title><p>A total of 301 COVID-19 patients were involved in this study, 236 cases were Males and 65 cases were Females Meanwhile age of patients were divided into five age groups; the majority of participants were aged between 40 - and 69 years (63.8%). Analogous to the mean length of infection was 3.00 &#177; 2.181 months, although 55.48 percent of the individuals had non-chronic illnesses. Additionally, it had been noted most common comorbidity was hypertension (11.6%) as shown in <xref ref-type="table" rid="table2">Table 2</xref>. Comparatively to the prevalence rate of Diabetes, Accompanied Disease was (9.6%), followed by (7%) had liver disease. Bronchial Disease was (6.3%), Heart disease and Autoimmune represented (2.7%). However, only (1.3%) of participants had a history of cancer disease.</p></sec><sec id="s3_2"><title>3.2. Symptoms of COVID-19 and Post-COVID-19</title><p>Regarding the signs and symptoms of infection. The most frequent answer given by respondents (56.8%) was fatigue. (<xref ref-type="table" rid="table3">Table 3</xref>) Then came fever, loss of taste and smell, coughing, and headache, with 44.2%, 40.2%, 31%, and 24.9% of those surveyed reporting each, respectively. But only 2.7% were symptom-free. In contrast, people who experienced symptoms that persisted after treatment</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Questionnaire of the presented study</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Part</th><th align="center" valign="middle" >Sector</th><th align="center" valign="middle"  colspan="5"  >Questions covered in survey</th></tr></thead><tr><td align="center" valign="middle"  rowspan="7"  >Part I</td><td align="center" valign="middle"  rowspan="7"  >Demographic information</td><td align="center" valign="middle"  rowspan="5"  >Age Groups</td><td align="center" valign="middle"  colspan="4"  >0 - 19 years old</td></tr><tr><td align="center" valign="middle"  colspan="4"  >20 - 39 years old</td></tr><tr><td align="center" valign="middle"  colspan="4"  >40 - 69 years old</td></tr><tr><td align="center" valign="middle"  colspan="4"  >70 - 89 years old</td></tr><tr><td align="center" valign="middle"  colspan="4"  >Above 90 years</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Gender</td><td align="center" valign="middle"  colspan="4"  >Male</td></tr><tr><td align="center" valign="middle"  colspan="4"  >Female</td></tr><tr><td align="center" valign="middle"  rowspan="11"  >Part II</td><td align="center" valign="middle"  rowspan="11"  >Relevant medical history</td><td align="center" valign="middle"  colspan="5"  >Do you have a Liver disease?</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Are you hypertensive?</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Are you Diabetic?</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Are you pregnant? (Females)</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Do you have any Cardiac problem or disease?</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Do you suffer from any Respiratory disease or problem?</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Did you have cancer?</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Do you have any type of Hepatitis? (Hepatitis B or C)</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Are you immunocompromised or having any sort of autoimmune disease?</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Do you have any other medical problem or disease (not mentioned)?</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Do you have an accompanied Disease?</td></tr><tr><td align="center" valign="middle"  rowspan="6"  >Part III</td><td align="center" valign="middle"  rowspan="6"  >Infection date</td><td align="center" valign="middle"  colspan="5"  >Since two-months</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Since three-months</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Since four-months</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Since five-months</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Since six-months</td></tr><tr><td align="center" valign="middle"  colspan="5"  >More than six months</td></tr><tr><td align="center" valign="middle"  rowspan="16"  >Part IV</td><td align="center" valign="middle"  rowspan="16"  >After-infection symptoms</td><td align="center" valign="middle"  colspan="3"   rowspan="16"  >Are you affected by the following conditions?</td><td align="center" valign="middle"  colspan="2"  >Asymptomatic</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Stomachache</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Lung problems</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Fatigue</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Fever</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Depression</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Sore Throat</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Cough</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Chronic Sinusitis</td></tr><tr><td align="center" valign="middle"  colspan="2"  >New Loss of sense of taste and smelling</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Diarrhea</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Headaches</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Other symptoms</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Hair lost</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Diabetes</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Urinary tract infections</td></tr><tr><td align="center" valign="middle"  rowspan="14"  >Part V</td><td align="center" valign="middle"  rowspan="14"  >Post-cure symptoms</td><td align="center" valign="middle"  colspan="3"   rowspan="14"  >Do you still have these symptoms?</td><td align="center" valign="middle"  colspan="2"  >Asymptomatic</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Hair lost</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Hyperglycemia</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Recurrent urinary tract infections</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Gastrointestinal problems</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Lung problems</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Fever</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Cough</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Fatigue</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Depression</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Headaches</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Nasal infections</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Lost of sense of taste and smelling</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Other symptoms</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >Part VI</td><td align="center" valign="middle"  rowspan="5"  >Disease severity</td><td align="center" valign="middle"  colspan="3"   rowspan="5"  >During onset of active infection, it was</td><td align="center" valign="middle"  colspan="2"  >Sever (I needed admission to ICU)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Moderate (I needed Oxygen)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Mild (I needed drugs only)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Very mild (I didn’t had drugs)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Without symptoms</td></tr><tr><td align="center" valign="middle"  rowspan="7"  >Part VII</td><td align="center" valign="middle"  rowspan="7"  >Vaccination</td><td align="center" valign="middle"  colspan="5"  >Didn’t reserved a vaccine</td></tr><tr><td align="center" valign="middle"  colspan="2"   rowspan="6"  >I did get the vaccine</td><td align="center" valign="middle"  colspan="2"   rowspan="6"  >Type</td><td align="center" valign="middle" >Astra Zeneca</td></tr><tr><td align="center" valign="middle" >Pfizer</td></tr><tr><td align="center" valign="middle" >Moderna</td></tr><tr><td align="center" valign="middle" >Sinopharm BIBP</td></tr><tr><td align="center" valign="middle" >Sputnik V</td></tr><tr><td align="center" valign="middle" >Other type</td></tr><tr><td align="center" valign="middle"  rowspan="8"  >Part VIII</td><td align="center" valign="middle"  rowspan="8"  >Treatment</td><td align="center" valign="middle"  colspan="5"  >I had reserved treatment in hospital</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Vitamins and minerals such as Vitamin C, Iron, Zinc and analgesic</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Vitamins as well as Antibiotics</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Vitamins, Antibiotics, Anticoagulants and Hydrocortisone</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Oxygen, Vitamins, Antibiotics, Anticoagulants and Hydrocortisone</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Home remedies and herbs</td></tr><tr><td align="center" valign="middle"  colspan="5"  >I didn’t had any type of Therapy</td></tr><tr><td align="center" valign="middle"  colspan="5"  >I had other different protocol</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Baseline characteristics of study participants</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Characteristics</th><th align="center" valign="middle"  colspan="2"  >N (%)</th></tr></thead><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" >65 (21.6%) Females</td><td align="center" valign="middle" >236 (78.1%) Males</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >Age group</td><td align="center" valign="middle"  colspan="2"  >0 - 19 years old (6.6%)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >20 - 30 years old (20.9%)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >40 - 60 years old (63.8%)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >70 - 89 years old (8.3%)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Above 90 years (0.3%)</td></tr><tr><td align="center" valign="middle" >Length of infection</td><td align="center" valign="middle"  colspan="2"  >3.00 &#177; 2.181</td></tr><tr><td align="center" valign="middle" >Non-chronic disease</td><td align="center" valign="middle"  colspan="2"  >167 (55.48%)</td></tr><tr><td align="center" valign="middle" >Diabetes</td><td align="center" valign="middle"  colspan="2"  >29 (9.6%)</td></tr><tr><td align="center" valign="middle" >Liver disease</td><td align="center" valign="middle"  colspan="2"  >2 (7%)</td></tr><tr><td align="center" valign="middle" >Bronchial Disease</td><td align="center" valign="middle"  colspan="2"  >19 (6.3%)</td></tr><tr><td align="center" valign="middle" >Autoimmune</td><td align="center" valign="middle"  colspan="2"  >8 (2.7%)</td></tr><tr><td align="center" valign="middle" >Heart disease</td><td align="center" valign="middle"  colspan="2"  >8 (2.7%)</td></tr><tr><td align="center" valign="middle" >Cancer</td><td align="center" valign="middle"  colspan="2"  >4 (1.3%)</td></tr><tr><td align="center" valign="middle" >Hypertension</td><td align="center" valign="middle"  colspan="2"  >35 (11.6%)</td></tr><tr><td align="center" valign="middle" >Accompanied Disease</td><td align="center" valign="middle"  colspan="2"  >29 (9.6%)</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The signs of infection both before and after</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >COVID-19 Symptom</th><th align="center" valign="middle" >N (%)</th><th align="center" valign="middle" >POST COVID-19 Symptom</th></tr></thead><tr><td align="center" valign="middle" >Stomachache</td><td align="center" valign="middle" >53 (17.6%)</td><td align="center" valign="middle" >11 (3.7%)</td></tr><tr><td align="center" valign="middle" >Lung Problem</td><td align="center" valign="middle" >21 (7%)</td><td align="center" valign="middle" >19 (6.3%)</td></tr><tr><td align="center" valign="middle" >Fatigue</td><td align="center" valign="middle" >171 (56.8%)</td><td align="center" valign="middle" >67 (22.3%)</td></tr><tr><td align="center" valign="middle" >Fever</td><td align="center" valign="middle" >133 (44.2%)</td><td align="center" valign="middle" >4 (1.3%)</td></tr><tr><td align="center" valign="middle" >Symptomless</td><td align="center" valign="middle" >8 (2.7%)</td><td align="center" valign="middle" >16 (5.3%)</td></tr><tr><td align="center" valign="middle" >Depression</td><td align="center" valign="middle" >62 (20.6%)</td><td align="center" valign="middle" >23 (7.6%)</td></tr><tr><td align="center" valign="middle" >Sore Throat</td><td align="center" valign="middle" >72 (23.9%)</td><td align="center" valign="middle" >4 (1.3%)</td></tr><tr><td align="center" valign="middle" >Cough</td><td align="center" valign="middle" >95 (31.9%)</td><td align="center" valign="middle" >41 (13.6%)</td></tr><tr><td align="center" valign="middle" >Chronic Sinusitis</td><td align="center" valign="middle" >35 (11.6%)</td><td align="center" valign="middle" >16 (5.3%)</td></tr><tr><td align="center" valign="middle" >Net Loss of Smell and Taste</td><td align="center" valign="middle" >121 (40.2%)</td><td align="center" valign="middle" >53 (17.6%)</td></tr><tr><td align="center" valign="middle" >Diarrhea</td><td align="center" valign="middle" >20 (6.6%)</td><td align="center" valign="middle" >----</td></tr><tr><td align="center" valign="middle" >Headache</td><td align="center" valign="middle" >75 (24.9%)</td><td align="center" valign="middle" >31 (10.3%)</td></tr><tr><td align="center" valign="middle" >Other Symptoms</td><td align="center" valign="middle" >19 (6.3%)</td><td align="center" valign="middle" >34 (11.3%)</td></tr><tr><td align="center" valign="middle" >Hair Loss</td><td align="center" valign="middle" >-------</td><td align="center" valign="middle" >33 (11%)</td></tr><tr><td align="center" valign="middle" >Diabetes</td><td align="center" valign="middle" >--------</td><td align="center" valign="middle" >11 (3.7%)</td></tr><tr><td align="center" valign="middle" >Urinary tract Infection</td><td align="center" valign="middle" >---------</td><td align="center" valign="middle" >5 (1.7%)</td></tr></tbody></table></table-wrap><p>included weariness (22.3%), a loss of taste and smell (17.6%), and fever (about 1.3%). 17.6% of respondents reported losing their sense of taste and smell, while little under 1.3% of persons experienced a temperature, as well as it was observed in <xref ref-type="fig" rid="fig1">Figure 1</xref> that males were exposed to PCS to a higher degree than females.</p></sec><sec id="s3_3"><title>3.3. Severity of Disease and Treatment</title><p>The ramification of disease severity was classified according to symptoms and treatments used, into five categories (ranging from symptoms-less without any medication to very severe for people hospitalized in ICU), 13% of those treated experienced a severe infection, compared to mild infections in 71.4% of individuals. <xref ref-type="table" rid="table4">Table 4</xref> shows that 5% of participants had very severe infections, while 9% of participants had very mild illnesses.</p><p><xref ref-type="table" rid="table5">Table 5</xref> reveals that nearly all of the subjects (37.9%) obtained treatment with vitamins, analgesics, and minerals, with 24.6% of participants receiving treatment with vitamins and antibiotics. In severe cases, 5.0% of patients received oxygen therapy, cortisone, and an anticoagulant. Just 5.3% of patients have not received any treatment, to add to that. 5.6% of patients chose home remedies, whereas 6.3% of patients were admitted to the hospital.</p></sec><sec id="s3_4"><title>3.4. Vaccination</title><p>Recipients were questioned regarding the COVID-19 vaccine. In 61.8% of cases, respondents claimed they had not had any vaccinations. The percentage of others who received the various vaccination kinds was as follows: 12.3%, 11%, and 6.6%, respectively, for AstraZeneca, Sinopharm, and Sputnik. (<xref ref-type="table" rid="table6">Table 6</xref>)</p></sec><sec id="s3_5"><title>3.5. Statistical Analysis</title><p>The Pearson Chi-Square and Fisher’s Exact test were used to determining the extent of the correlation between the various variables, therefore, the results were divided into a strong relationship with a significant p-value less than (0.05) and weak or insignificant (p-value &gt; 0.05). In this study, we noticed the severity of disease was highly dependent on hypertension and diabetes with 0.003, 0.01 p-values respectively, the same situation with gender, age as well as post covid syndrome (PCS) with p-value (0.002, 0.016) respectively, in addition to Diabetes and cough, with p-value (0.004) respectively. Whereas in the case of cough, diarrhea, headache, age, treatment protocol, and post-COVID syndrome the</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Severity of disease</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Severity of Disease</th><th align="center" valign="middle" >Frequency</th><th align="center" valign="middle" >Percent %</th></tr></thead><tr><td align="center" valign="middle" >Very Severe</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >5.0</td></tr><tr><td align="center" valign="middle" >Sever</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >13.0</td></tr><tr><td align="center" valign="middle" >Mild</td><td align="center" valign="middle" >215</td><td align="center" valign="middle" >71.4</td></tr><tr><td align="center" valign="middle" >Very mild</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >9.0</td></tr><tr><td align="center" valign="middle" >Symptoms-Less</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1.7</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >301</td><td align="center" valign="middle" >100.0</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Treatments used during COVID-19 Infection</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Treatment</th><th align="center" valign="middle" >Frequency</th><th align="center" valign="middle" >Percent</th></tr></thead><tr><td align="center" valign="middle" >Vitamins, analgesics, and Minerals</td><td align="center" valign="middle" >114</td><td align="center" valign="middle" >37.9</td></tr><tr><td align="center" valign="middle" >Vitamins and Antibiotic</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >24.6</td></tr><tr><td align="center" valign="middle" >Vitamins and Antibiotic Cortisone, Anticoagulant</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >3.3</td></tr><tr><td align="center" valign="middle" >O<sub>2</sub> and Vitamins and Antibiotic Cortisone, Anticoagulant</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >5.0</td></tr><tr><td align="center" valign="middle" >Home Remedies</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >5.6</td></tr><tr><td align="center" valign="middle" >No Treatment</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >5.3</td></tr><tr><td align="center" valign="middle" >Hospitalization</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >6.3</td></tr><tr><td align="center" valign="middle" >Different Protocol</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >12.0</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >301</td><td align="center" valign="middle" >100.0</td></tr></tbody></table></table-wrap><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Description of the type of vaccination</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Type of vaccine</th><th align="center" valign="middle" >Frequency</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >No-Vaccination</td><td align="center" valign="middle" >186</td><td align="center" valign="middle" >61.8</td></tr><tr><td align="center" valign="middle" >Sinovac</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >3.7</td></tr><tr><td align="center" valign="middle" >Sinofarm</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >11.0</td></tr><tr><td align="center" valign="middle" >Sputnik</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >6.6</td></tr><tr><td align="center" valign="middle" >AstraZeneca</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >12.3</td></tr><tr><td align="center" valign="middle" >other</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >4.7</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >301</td><td align="center" valign="middle" >100.0</td></tr></tbody></table></table-wrap><p>correlation was denied depending on their insignificant p-value recorded as follows (0.407, 0.611, 0.052, 0.105).</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>In the current study, we focused on the prevalence as well as characteristics of the Post-COVID Syndrome(PCS) in a population consisting of 301 COVID-19 convalescent patients, where, COVID-19 is a new disease with a narrow range of information on the PCS (Galal, et al., 2021) [<xref ref-type="bibr" rid="scirp.130196-ref13">13</xref>] . Based on the current findings, there were 78.1% more Males than Females in the sample, and 63.8% of participants were between the ages of 40 and 69. This discovery may be related to the fact that chronic diseases begin to manifest at this age, while SARS-CoV-2 infection prevalence peaked at the age of forty. The previous finding was consistent with Kayaaslan’s findings (Kayaaslan et al., 2021) [<xref ref-type="bibr" rid="scirp.130196-ref14">14</xref>] , but they were in conflict with Galal et al.’s findings (Galal, et al., 2021) [<xref ref-type="bibr" rid="scirp.130196-ref13">13</xref>] , where a significant portion of their cohort was in the age range of 21 to 40. Compared to M. Augustin et al. (2021) [<xref ref-type="bibr" rid="scirp.130196-ref15">15</xref>] almost all of the current cohort (71.04%) had mild COVID-19 infection with mild symptoms, while only 13% and 5%, respectively, had severe and extremely severe SARS-CoV-2 infections. Regarding the mentioned before most of the cohort had mild infections where they were not hospitalized during the acute phase and the mean length of infection was 3.00 &#177; 2.181 months. Recently, the time span to qualify for the post syndrome was &gt; 28 - 30 days - 60 days (Sudre CH. 2020) [<xref ref-type="bibr" rid="scirp.130196-ref16">16</xref>] , or more than 3 months (Townsend L et al. 2020 [<xref ref-type="bibr" rid="scirp.130196-ref17">17</xref>] , Carvalho-Schneider C, et al., 2020 [<xref ref-type="bibr" rid="scirp.130196-ref18">18</xref>] .</p><p>Prior to acquiring COVID-19, 55.48% of participants did not have any chronic diseases, while comparable studies revealed that 75% of patients did not have any comorbid disorders (Hussein et al., 2020) [<xref ref-type="bibr" rid="scirp.130196-ref19">19</xref>] . Conversely, the most prevalent co-occurring diseases in the population were hypertension, bronchial disease, diabetes, and liver disease. On the other hand, heart issues, autoimmune diseases, and cancer diseases, which were consistent with M. Augustin et al. (2021) [<xref ref-type="bibr" rid="scirp.130196-ref15">15</xref>] , and Lechien JR et al. (2020) [<xref ref-type="bibr" rid="scirp.130196-ref20">20</xref>] findings demonstrate the minor frequency of associated illness.</p><p>Analogous to COVID-19 infection symptoms 8 (2.7%) patients of 301 their infection was symptomless while more than half of participants (56.8%) had fatigue as an apparent symptom followed by fever, New Loss of sense of taste and smell (44.2%, 40.2% respectively). Whereas, Headache was not the most prevalent symptom (24.9%), which was in contrast with Lechien JR results where they found that headache is the most prevalent symptom at the onset of illness followed by a new loss of sense of taste and smell. on the other hand, our findings were in line with Morgul, et al., (2021) [<xref ref-type="bibr" rid="scirp.130196-ref21">21</xref>] who found that 64.1% of participants suffered from fatigue as an observed symptom.</p><p>Recently, it has become clear that some SARS-CoV-2 infection convalescent patients continued to have some symptoms for a period reached to months after the onset of COVID-19 infection without considering the severity of the disease (Chopra V et al., 2020) [<xref ref-type="bibr" rid="scirp.130196-ref22">22</xref>] . Up to now, there is no exact terminology to define this case, there for, this clinical case may expressed as long COVID (Mandal S, et al. 2021) [<xref ref-type="bibr" rid="scirp.130196-ref23">23</xref>] , chronic COVID syndrome(Baig AM, 2020) [<xref ref-type="bibr" rid="scirp.130196-ref24">24</xref>] , post-acute COVID-19 syndrome(IDSA, 2020) and post-COVID syndrome (Goertz YMJ et al., 2020) [<xref ref-type="bibr" rid="scirp.130196-ref25">25</xref>] . In the current study, we choose Post-COVID Syndrome (PCS).</p><p>We found that whereas 94.7% of the population had PCS and fatigue was the most commonly reported persistent symptom with the findings of Townsend L et al. (2020) [<xref ref-type="bibr" rid="scirp.130196-ref17">17</xref>] and Marshall M et al. (2020) [<xref ref-type="bibr" rid="scirp.130196-ref26">26</xref>] , just sixteen (5.3%) of the COVID-19 treated patients had no post-COVID symptoms. One of the most recurrences of COVID-19 lasting symptoms was fatigue, which may be caused by brain capillary endothelial dysfunction, as reported by Nauen DW et al. in 2021 [<xref ref-type="bibr" rid="scirp.130196-ref27">27</xref>] . Fatigue was followed by a fresh loss of taste and smell, followed by a persistent cough in 13.6% of participants, which was the post-symptom, the outcomes were consistent with an Italian study. (Angelo Carf et al. 2020) [<xref ref-type="bibr" rid="scirp.130196-ref28">28</xref>]</p><p>Synonymous to vaccinations, 61.8% of participants rejected to take advantage of the available COVID vaccine, which may have been because they had sufficient knowledge about the vaccine or were reluctant to have one. The adverse effects of the vaccinations and the lack of confidence in their efficacy may also be contributing factors to the population’s resistance to the vaccine. This finding was consistent with a related Ethiopian study (Delelegn Yehualashet, et al., 2022) [<xref ref-type="bibr" rid="scirp.130196-ref29">29</xref>] Other participants were given vaccines from Sinovac, Sinofarm, Sputnik, AstraZeneca, as well as additional manufactured vaccines. Astrazeneca’s percentage was larger than the others because it is suggested for older age groups.</p><p>Corresponding to our research 37.9% received oral vitamins, minerals and analgesics as a treatment for COVID-19 infection, while 24.6% of the contributors used oral antibiotics over the vitamins, minerals, and analgesics. However, only 5% of the patients received oxygen therapy, cortisone, and anticoagulant, and 6.3% of contributors were hospitalized. The results mentioned previously confirm that mild cases were prevalent in general and that serious instances were extremely uncommon in the cohort. Thus only 5.3% did not receive any therapy which in contrast with Lechien JR finding where they revealed that about 29% of the patients did not receive any drug and about 7% had antibiotics.</p><p>In the current study, PCS was independently predicted by diarrhea, cough, and headache following acute COVID-19 infection (p-values 0.611, 0.407, and 0.052 respectively). While diarrhea at the time of disease onset was an independent predictor for PCS, gender was a dependent indicator for PCS with a p-value of 0.002, which was consistent with research by M. Augustin et al. from 2021 [<xref ref-type="bibr" rid="scirp.130196-ref15">15</xref>] . In contrast, men are more likely than women in our research to be accepted for PCS. Furthermore, age is a dependent predictor for long-term COVID-19 symptoms, they revealed that cases older than 65 have more acceptability to have PCS than people aged from 18 to 64. The p-value for this relationship was 0.016, which was in accordance with Bull-Otterson et al.’s findings in 2022 [<xref ref-type="bibr" rid="scirp.130196-ref30">30</xref>] .</p><p>Considering the comorbidities of the cohort applicant, diabetes and hypertension were associated with an increased risk of having a severe condition, with a p-value of 0.05 indicating a relationship between the severity of the disease and them. Also Peng, M., et al. (2021) [<xref ref-type="bibr" rid="scirp.130196-ref31">31</xref>] reported that myocardial damage from COVID-19 infection and long-term hypertension may both cause organ damage, including heart injury. Similarly, they demonstrated that hypertension has a crucial role in controlling the immune system, the gastrointestinal system, and inflammation, which shows the severity of the COVID-19 disease in hypertensive patients. Sen, S., et al. [<xref ref-type="bibr" rid="scirp.130196-ref32">32</xref>] , further indicate that diabetes is linked to decreased body immunity and increased SARS-CoV-2 replication, which may be an indicator of the severity of COVID-19 disease. On the other hand, there was a significant correlation between diabetes as a comorbid condition and cough as a PCS (p-value = 0.004), which was consistent with Li, G., et al.’s (2020) [<xref ref-type="bibr" rid="scirp.130196-ref33">33</xref>] finding that the cough may be a more prevalent feature of SARS-CoV-2 infection in diabetic patients than in non-diabetic patients. Finally, the treatment approach that had been used in Libya to treat Covid-19 infected patients had no effect on preventing PCS in those who survived, where the p-value was 0.105 which was contraindicated with Xie Y., et al. (2023) [<xref ref-type="bibr" rid="scirp.130196-ref34">34</xref>] results, based on findings showed that utilizing the antiviral drug (nirmatrelvir) is linked to a decrease in the long-lasting Covid-19 effects.</p><p>Our study discussed PCS in the population who were not admitted to or attended by hospitals, and we concentrated on all PCS rather than just two or three, from which participants may select the recurrent symptoms they experienced. However, smoking was not considered a characteristic of PCS in the current investigation. Alternatively, comorbidity was evaluated as a criterion for SARS-CoV-2 convalescent patients. Further, the questionnaires were assigned at random throughout the city using several techniques, including in-person and online. In comparison, the males were quite more than females in our cohort.</p></sec><sec id="s5"><title>5. Conclusion</title><p>The COVID-19 disease and Post-COVID Syndrome (PCS) were reviewed in the present research, which revealed many criteria that had an impact on them. The most frequent persistent symptoms (PCS) reported by patients for longer than two months were fatigue, new loss of taste as well as smell, and cough. Less frequently reported PCS included lung problems, headaches, and diabetes. In Benghazi’s population, the symptoms were more persistent in the males than the females, Additional signs like diarrhea and headaches did not point to PCS. It should confirm that PCS can manifest even in those with moderate SARS-CoV-2 infections.</p></sec><sec id="s6"><title>Acknowledgments</title><p>To all Benghazi COVID-19 survivors.</p></sec><sec id="s7"><title>Ethics Statements</title><p>The team had verbal consent from subjects before answering questionnaire.</p></sec><sec id="s8"><title>Author Contribution</title><p>The authors confirm contribution to the paper as follows: study conception and design: Asma M. Buzgeia, Nazik M. Hamad; data collection: Asma M. Buzgeia, Nazik M. Hamad; analysis and interpretation of results: Nuri H. Badi.; draft manuscript preparation: Fatma Mohamed Ali. All authors reviewed the results and approved the final version of the manuscript.</p></sec><sec id="s9"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="s10"><title>Cite this paper</title><p>Buzgeia, A.M., Badi, N.H.S., Ali, F.M.B. and Hamad, N.M.A. (2023) Cross-Sectional Perspective Study of Post-COVID Syndrome Characteristics in Benghazi, Libya. Open Access Library Journal, 10: e11004. https://doi.org/10.4236/oalib.1111004</p></sec></body><back><ref-list><title>References</title><ref id="scirp.130196-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Lone, S.A. and Ahmad, A. (2020) COVID-19 Pandemic—An African Perspective. Emerging Microbes &amp; Infections, 9, 1300-1308.  
https://doi.org/10.1080/22221751.2020.1775132</mixed-citation></ref><ref id="scirp.130196-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Shi, Z.L., et al. (2020) Apneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature, 579, 270-273. https://doi.org/10.1038/s41586-020-2012-7</mixed-citation></ref><ref id="scirp.130196-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Singhal, T. (2020) A Review of Coronavirus Disease-2019 (COVID-19). The Indian Journal of Pediatrics, 87, 281-286. https://doi.org/10.1007/s12098-020-03263-6</mixed-citation></ref><ref id="scirp.130196-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kampf, G., Todt, D., Pfaender, S. and Steinmann, E. (2020) Persistence of Coronaviruses on Inanimate Surfaces and Their Inactivation with Biocidal Agents. Journal of Hospital Infection, 104, 246-251. https://doi.org/10.1016/j.jhin.2020.01.022</mixed-citation></ref><ref id="scirp.130196-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Shi, Y., Wang, G., Cai, X.P., Deng, J.W., Zheng, L., Zhu, H.H., Chen, Z., et al. (2020) An Overview of COVID-19. Journal of Zhejiang University—SCIENCE B, 21, 343-360. https://doi.org/10.1631/jzus.B2000083</mixed-citation></ref><ref id="scirp.130196-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Sharma, A., Tiwari, S., Deb, M.K. and Marty, J.L. (2020) Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): A Global Pandemic and Treatment Strategies. International Journal of Antimicrobial Agents, 56, Article ID: 106054.  
https://doi.org/10.1016/j.ijantimicag.2020.106054</mixed-citation></ref><ref id="scirp.130196-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Rothan, H.A. and Byrareddy, S.N. (2020) The Epidemiology and Pathogenesis of Coronavirus Disease (COVID-19) Outbreak. Journal of Autoimmunity, 109, Article ID: 102433. https://doi.org/10.1016/j.jaut.2020.102433</mixed-citation></ref><ref id="scirp.130196-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Davis, H.E., et al. (2021) Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. eClinicalMedicine, 38, Article ID: 101019.  
https://doi.org/10.1016/j.eclinm.2021.101019</mixed-citation></ref><ref id="scirp.130196-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gao, Y.D., Ding, M., Dong, X., Zhang, J.J., KursatAzkur, A., Azkur, D. and Akdis, C.A. (2021) Risk Factors for Severe and Critically Ill COVID-19 Patients: A Review. Allergy, 76, 428-455. https://doi.org/10.1111/all.14657</mixed-citation></ref><ref id="scirp.130196-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Scordo, K.A., Richmond, M.M. and Munro, N. (2021) Post-COVID-19 Syndrome: Theoretical Basis, Identification, and Management. AACN Advanced Critical Care, 32, 188-194. https://doi.org/10.4037/aacnacc2021492</mixed-citation></ref><ref id="scirp.130196-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yong, S.J. (2021) Long COVID or Post-COVID-19 Syndrome: Putative Pathophysiology, Risk Factors, and Treatments. Infectious Diseases, 53, 737-754.  
https://doi.org/10.1080/23744235.2021.1924397</mixed-citation></ref><ref id="scirp.130196-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Halpin, S.J., McIvor, C., Whyatt, G., Adams, A., Harvey, O., McLean, L., Sivan, M., et al. (2021) Postdischarge Symptoms and Rehabilitation Needs in Survivors of COVID-19 Infection: A Cross-Sectional Evaluation. Journal of Medical Virology, 93, 1013-1022. https://doi.org/10.1002/jmv.26368</mixed-citation></ref><ref id="scirp.130196-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Galal, I., Hussein, A.A., Amin, M.T., Saad, M.M., Zayan, H.E.E., Abdelsayed, M.Z., Hashem, M.K., et al. (2021) Determinants of Persistent Post-COVID-19 Symptoms: Value of a Novel COVID-19 Symptom Score. The Egyptian Journal of Bronchology, 15, Article No. 10. https://doi.org/10.1186/s43168-020-00049-4</mixed-citation></ref><ref id="scirp.130196-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kayaaslan, B., Eser, F., Kalem, A.K., Kaya, G., Kaplan, B., Kacar, D., Guner, R., et al. (2021) Post-COVID Syndrome: A Single-Center Questionnaire Study on 1007 Participants Recovered from COVID-19. Journal of Medical Virology, 93, 6566-6574.  
https://doi.org/10.1002/jmv.27198</mixed-citation></ref><ref id="scirp.130196-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Augustin, M., Schommers, P., Stecher, M., et al. (2021) Post-COVID Syndrome in Non-Hospitalised Patients with COVID-19: A Longitudinal Prospective Cohort Study. The Lancet Regional Health—Europe, 6, Article ID: 100122.  
https://doi.org/10.1016/j.lanepe.2021.100122</mixed-citation></ref><ref id="scirp.130196-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Sudre, C.H. (2021) Attributes and Predictors of Long-Covid: Analysis of Covid Cases and Their Symptoms Collected by the Covid Symptoms Study App. Nature Medecine, 27, 626-631. https://doi.org/10.1101/2020.10.19.20214494</mixed-citation></ref><ref id="scirp.130196-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Townsend, L., Dyer, A.H., Jones, K., Dunne, J., Mooney, A. and Gaffney, F (2020) Persistent Fatigue following SARS-CoV-2 Infection Is Common and Independent of Severity of Initial Infection. PLOS ONE, 15, e0240784.  
https://doi.org/10.1371/journal.pone.0240784</mixed-citation></ref><ref id="scirp.130196-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Carvalho-Schneider, C., Laurent, E., Lemaignen, A., Beaufils, E., Bourbao-Tournois, C. and Laribi, S. (2021) Follow-Up of Adults with Noncritical COVID-19 Two Months after Symptom Onset. Clinical Microbiology and Infection, 27, 258-263.  
https://doi.org/10.1016/j.cmi.2020.09.052</mixed-citation></ref><ref id="scirp.130196-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Hussein, A.A.M., Galal, I., Saad, M.M., Zayan, H.E.E., Abdelsayed, M.Z., Moustafa, M.M. and Abdelrheem, S.S. (2020) Post-COVID-19 Functional Status: Relation to Age, Smoking, Hospitalization and Comorbidities. Annals of Thoracic Medicine, 16, 260-265.</mixed-citation></ref><ref id="scirp.130196-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Angelo, C., Bernabei, R., Landi, F. and Gemelli against COVID-19 Post-Acute Care Study Group (2020) Persistent Symptoms in Patients after Acute COVID-19. JAMA, 324, 603-605. https://doi.org/10.1001/jama.2020.12603</mixed-citation></ref><ref id="scirp.130196-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Delelegn, Y., Seboka, B.T., Tesfa, G.A., Mamo, T.T., Yawo, M.N. and Hailegebreal, S. (2022) Prevalence and Determinants of COVID-19 Vaccine Hesitancy among the Ethiopian Population: A Systematic Review. Risk Management and Healthcare Policy, 15, 1433-1445. https://doi.org/10.2147/RMHP.S368057</mixed-citation></ref><ref id="scirp.130196-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Bull-Otterson, L., Baca, S. and Saydah, S. (2022) Post-Covid Conditions among Adults COVID-19 Survivors Aged 18-64 and &gt; 65 Years-United States. Morbidity and Mortality Weekly Report, 71, 713-717.  
https://doi.org/10.15585/mmwr.mm7121e1</mixed-citation></ref><ref id="scirp.130196-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Peng, M., He, J., Xue, Y., Yang, X., Liu, S. and Gong, Z. (2021) Role of Hypertension on the Severity of COVID-19: A Review. Journal of Cardiovascular Pharmacology, 78, e648-e655. https://doi.org/10.1097/FJC.0000000000001116</mixed-citation></ref><ref id="scirp.130196-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Sen, S., Chakraborty, R., Kalita, P. and Pathak, M.P. (2021) Diabetes Mellitus and COVID-19: Understanding the Association in Light of Current Evidence. World Journal of Clinical Cases, 9, 8327-8339. https://doi.org/10.12998/wjcc.v9.i28.8327</mixed-citation></ref><ref id="scirp.130196-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Li, G., Deng, Q., Feng, J., Li, F., Xiong, N. and He, Q. (2020) Clinical Characteristics of COVID-19 Patients with and without Diabetes in Wuhan Red Cross Hospital. Journal of Diabetes Research, 2020, Article ID: 1652403.  
https://doi.org/10.1155/2020/1652403</mixed-citation></ref><ref id="scirp.130196-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Xie, Y., Choi, T. and Al-Aly, Z. (2023) Association of Treatment with Nirmatrelvir and the Risk of Post-COVID-19 Condition. JAMA Internal Medicine, 183, 554-564.  
https://doi.org/10.1001/jamainternmed.2023.0743</mixed-citation></ref><ref id="scirp.130196-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Nauen, D.W., Hooper, J.E., Stewart, C.M. and Solomon, I.H. (2021) Assessing Brain Capillaries in Coronavirus Disease 2019. JAMA Neurology, 78, 760-762.  
https://doi.org/10.1001/jamaneurol.2021.0225</mixed-citation></ref><ref id="scirp.130196-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Marshall, M. (2020) The Lasting Misery of Coronavirus Long-Haulers. Nature, 585, 339-341. https://doi.org/10.1038/d41586-020-02598-6</mixed-citation></ref><ref id="scirp.130196-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Goertz, Y.M.J., Van Herck, M., Delbressine, J.M., Vaes, A.W., Meys, R. and Machado, F.V.C. (2020) Persistent Symptoms 3 Months after a SARS-CoV-2 Infection: The Post-COVID-19 Syndrome. ERJ Open Research, 6, 00542-2020.</mixed-citation></ref><ref id="scirp.130196-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Baig, A.M., Khaleeq, A., Ali, U. and Syeda, H. (2020) Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chemical Neuroscience, 11, 995-998.  
https://doi.org/10.1021/acschemneuro.0c00122</mixed-citation></ref><ref id="scirp.130196-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Mandal, S., Barnett, J., Brill, S.E., Brown, J.S., Denneny, E.K. and Hare, S.S. (2021) Long-COVID’: Across-Sectional Study of Persisting Symptoms, Biomarker and Imaging Abnormalities Following Hospitalisation for COVID-19. Thorax, 76, 396-398. https://doi.org/10.1136/thoraxjnl-2020-215818</mixed-citation></ref><ref id="scirp.130196-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Chopra, V., Flanders, S.A., O’Malley, M., Malani, A.N. and Prescott, H.C. (2020) Sixty-Day Outcomes among Patients Hospitalized with COVID-19. Annals of Internal Medicine, 174, 576-578. https://doi.org/10.7326/M20-5661</mixed-citation></ref><ref id="scirp.130196-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Morgul, E., Bener, A., Atak, M., Akyel, S., Aktas, S., Bhugra, D., Jordan, T.R., et al. (2021) COVID-19 Pandemic and Psychological Fatigue in Turkey. International Journal of Social Psychiatry, 67, 128-135.  
https://doi.org/10.1177/0020764020941889</mixed-citation></ref><ref id="scirp.130196-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Lechien, J.R., Chiesa-Estomba, C.M., Place, S., Van Laethem, Y., Cabaraux, P. and Mat, Q. (2020) Clinical and Epidemiological Characteristics of 1420 European Patients with Mild-to-Moderate Coronavirus Disease 2019. Journal of Internal Medicine, 288, 335-344. https://doi.org/10.1111/joim.13089</mixed-citation></ref></ref-list></back></article>